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BACKGROUND
Universal antiretroviral therapy (ART) with annual population testing and a multidisease, 
patient-centered strategy could reduce new human immunodeficiency virus (HIV) infec-
tions and improve community health.
METHODS
We randomly assigned 32 rural communities in Uganda and Kenya to baseline HIV and 
multidisease testing and national guideline–restricted ART (control group) or to baseline 
testing plus annual testing, eligibility for universal ART, and patient-centered care (inter-
vention group). The primary end point was the cumulative incidence of HIV infection at 
3 years. Secondary end points included viral suppression, death, tuberculosis, hyperten-
sion control, and the change in the annual incidence of HIV infection (which was evalu-
ated in the intervention group only).
RESULTS
A total of 150,395 persons were included in the analyses. Population-level viral suppression 
among 15,399 HIV-infected persons was 42% at baseline and was higher in the interven-
tion group than in the control group at 3 years (79% vs. 68%; relative prevalence, 1.15; 
95% confidence interval [CI], 1.11 to 1.20). The annual incidence of HIV infection in the 
intervention group decreased by 32% over 3 years (from 0.43 to 0.31 cases per 100 person-
years; relative rate, 0.68; 95% CI, 0.56 to 0.84). However, the 3-year cumulative incidence 
(704 incident HIV infections) did not differ significantly between the intervention group 
and the control group (0.77% and 0.81%, respectively; relative risk, 0.95; 95% CI, 0.77 to 
1.17). Among HIV-infected persons, the risk of death by year 3 was 3% in the intervention 
group and 4% in the control group (0.99 vs. 1.29 deaths per 100 person-years; relative risk, 
0.77; 95% CI, 0.64 to 0.93). The risk of HIV-associated tuberculosis or death by year 3 
among HIV-infected persons was 4% in the intervention group and 5% in the control 
group (1.19 vs. 1.50 events per 100 person-years; relative risk, 0.79; 95% CI, 0.67 to 0.94). 
At 3 years, 47% of adults with hypertension in the intervention group and 37% in the 
control group had hypertension control (relative prevalence, 1.26; 95% CI, 1.15 to 1.39).
CONCLUSIONS
Universal HIV treatment did not result in a significantly lower incidence of HIV infection 
than standard care, probably owing to the availability of comprehensive baseline HIV test-
ing and the rapid expansion of ART eligibility in the control group. (Funded by the Na-
tional Institutes of Health and others; SEARCH ClinicalTrials.gov number, NCT01864603.)
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Antiretroviral therapy (ART) has the dual benefit of improving the health of individual persons and of reducing 
transmission of human immunodeficiency virus 
(HIV) infection.1-3 With 1.8 million new HIV 
infections and 1.0 million deaths annually, it is 
clear that the full individual and public health 
gains from effective treatment of all HIV-infected 
persons have yet to be realized.4
New approaches to universal HIV treatment 
must overcome many barriers. An estimated 9.2 
million of the 36.9 million persons with HIV do 
not know their HIV status.4 Persons who receive 
a diagnosis of HIV infection face health care 
systems that are unresponsive to life-stage and 
gender-specific needs, have discriminatory poli-
cies, and lack patient-centered care.5,6 As a result, 
only an estimated 47% of persons living with 
HIV have viral suppression — far short of the 
73% target for 2020 set by the joint United Na-
tions Program on HIV/AIDS (UNAIDS). The 
challenge now is finding HIV-infected persons 
who are not currently receiving care for HIV 
and tailoring approaches to engage and retain 
those persons in care. We postulated that in 
rural Uganda and Kenya, reaching these persons 
would require addressing their health priorities 
beyond HIV, at a place they desire to attend, 
and with care centered on their needs. We con-
ducted a randomized trial to test the hypothesis 
that universal HIV treatment and annual testing 
delivered with a community-based, multidisease, 
patient-centered approach would result in a lower 
number of new HIV infections and better com-
munity health than the current standard of care.
Me thods
Trial Design and Population
The Sustainable East Africa Research in Com-
munity Health (SEARCH) trial was a cluster-
randomized trial that was conducted in three 
regions of rural Uganda and Kenya from 2013 
through 2017. The randomization units were 
communities of 9000 to 11,000 persons that 
were defined by recent national census and ad-
ministrative boundaries. A total of 54 communi-
ties in target regions were selected on the basis 
of criteria that included the presence of a gov-
ernment health clinic that provided ART and 
distance from other potential trial communities 
(Fig. S1 in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org). 
Communities were pair-matched on the basis of 
geographic region, population density, number 
of trading centers, variety of occupations, and 
mobility patterns. The best-matching 16 pairs 
were randomly assigned to baseline HIV testing 
and multidisease testing at health fairs and na-
tional guideline–restricted antiretroviral therapy 
(control group) or to baseline HIV and multidis-
ease testing plus annual testing, eligibility for uni-
versal antiretroviral therapy, and patient-centered 
care (intervention group) (Fig. S2 in the Supple-
mentary Appendix). Randomization was per-
formed at a participatory public event attended by 
community leaders and members.7 The trial pop-
ulation described in this report included all resi-
dents 15 years of age or older. After the release of 
the 2015 World Health Organization ART guide-
lines in which universal ART was recommended, 
the data and safety monitoring board approved a 
modification to the protocol that reduced the 
duration of follow-up for evaluation of the pri-
mary end point from 5 years to 3 years.8
Census
At baseline, we enumerated and enrolled resi-
dents with the use of a household census in 
partnership with community leaders. Demo-
graphic information, household socioeconomic 
information, migration data, and coordinates of 
the geographic location were collected at these 
visits.9 In addition to residents’ names, biometric 
identifiers based on each resident’s digital finger-
print were used to identify residents during their 
participation in testing and care activities in the 
community.
Community Health Campaigns
After completing the baseline census, we con-
ducted mobile, 2-week, multidisease health cam-
paigns under large tents in all communities 
during weekdays, evenings, and weekends in 
collaboration with local health units and the 
Ministry of Health in Uganda and in Kenya; for 
persons who did not attend the campaign, test-
ing was performed at their home or other loca-
tion of their choice.9 Persons who were found to 
have HIV infection, diabetes, or hypertension re-
ceived counseling and clinic appointments. HIV-
infected persons also had their CD4+ T-cell count 
and HIV RNA levels measured and received a 
one-time round-trip transportation voucher for 
the first clinic visit.9,10 Repeat campaigns includ-
ing HIV testing were conducted annually in the 
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intervention communities only. After 3 years, 
campaigns were conducted in all communities 
for assessment of the trial end points.
Antiretroviral Therapy and Treatment  
of Noncommunicable Disease
The SEARCH treatment intervention was designed 
to remove patient-level barriers and maximize 
the efficiency of the health care system. For HIV-
infected persons who were not receiving ART, 
appointments to initiate or restart ART were 
made as soon as possible, within 7 days at most, 
after HIV testing. To facilitate linkage to care, 
the clinic staff introduced themselves in person 
or by mobile phone, provided persons with a 
hotline that they could contact by telephone or 
text message if they had questions or needed 
support, and called or sent text messages for 
reminders about clinic visits. We provided patient-
centered care for HIV infection, diabetes, and 
hypertension at government clinics that were 
augmented by trial staff.11 Key components of 
care included 3-month visit intervals, f lexible 
hours, reduced wait time at clinics, and a wel-
coming staff. We offered ART to all persons with 
HIV infection. For persons who were assessed 
as ineligible to receive treatment on the basis of 
national guidelines, the trial provided efavirenz 
in combination with tenofovir–emtricitabine 
(Truvada), which was donated by Gilead Sciences. 
Gilead had no role in the design of the trial, in 
the collection or analysis of the data, or in the 
preparation of the manuscript, although an in-
dustry representative from Gilead was a member 
of the protocol team and scientific advisory 
board. For all persons who had hypertension or 
diabetes, care followed standard algorithms 
(Fig. S3 in the Supplementary Appendix).
At clinics in control communities, ART, hyper-
tension therapy, and diabetes therapy were pro-
vided in accordance with national guidelines. To 
mitigate staffing shortages that could slow im-
plementation of updated ART guidelines, we 
provided additional staff at control clinics. Con-
trol clinics implemented ART guidelines that 
were specific to Uganda and Kenya; during the 
trial, the threshold for eligibility for ART in 
these countries expanded from a specific CD4+ 
T-cell count (which had ranged from ≤350 cells 
per cubic millimeter to <500 cells per cubic mil-
limeter) to universal treatment (regardless of 
CD4+ T-cell count) (Fig. S4 in the Supplemen-
tary Appendix).
End Points
The primary end point of the trial was the cumu-
lative incidence of HIV infection (confirmed by 
the Bio-Rad Geenius HIV 1/2 Confirmatory As-
say and Western blot testing) at 3 years among 
residents enumerated in the baseline census 
(Table S1 in the Supplementary Appendix). Sec-
ondary end points associated with HIV infection 
included the interim annual incidence of HIV 
infection in the intervention group, the time to 
initiation of ART, and viral suppression (defined 
as HIV RNA <500 copies per milliliter). Second-
ary health end points included death, incident 
tuberculosis or death due to illness, and control 
of hypertension and diabetes among the HIV-
infected persons and in the overall population.
Trial Oversight
The trial protocol was approved by the ethics 
committees at the University of California, San 
Francisco; the Kenya Medical Research Institute; 
and Makerere University School of Medicine in 
Uganda. Community-level consent (described in 
the protocol) and oral informed consent from 
individual participants were provided for the 
census enumeration and the health campaigns, 
and written informed consent was provided in 
cases in which a participant was ineligible for 
ART on the basis of country guidelines. The 
trial was conducted in accordance with the prin-
ciples of the Declaration of Helsinki, with over-
sight by the data and safety monitoring board. 
The trial protocol and statistical analysis plan 
are available at NEJM.org. The authors vouch for 
the accuracy and completeness of the data and 
for the fidelity of the trial to the protocol.
Statistical Analysis
We estimated that the sample size of 32 com-
munities would provide 80% power to detect a 
cumulative incidence of HIV infection that was 
40% lower in the intervention group than in the 
control group under conservative assumptions 
(i.e., a cumulative incidence of 1% in the control 
group, a matched-pair coefficient of variation of 
0.4, and ≥2700 HIV-negative persons with out-
comes measured in each community). Under less 
conservative assumptions, including model-based 
simulations, the trial was powered to detect a 
cumulative incidence that was 25% lower in the 
intervention group than in the control group.
We compared the cumulative incidence of 
HIV infection in the two trial groups using a 
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two-stage approach. First, we calculated the per-
centage of HIV-negative residents who had sero-
conversion in each community. Next, we compared 
these percentages in the trial groups using 
community-level targeted maximum likelihood 
estimation; we selected adjustment variables (can-
didates included baseline prevalence of HIV in-
fection and male circumcision coverage) using 
cross-validation.12 Statistical inference was based 
on Student’s t-distribution with 15 degrees of free-
dom and accounted for the pair-matched design.
We used an analogous approach to compare 
the secondary end points in the two groups. 
Viral suppression, control of hypertension, and 
control of diabetes were estimated for each com-
munity; differences in characteristics between 
persons with measured outcomes and persons 
with missing outcomes were adjusted with the 
use of individual-level targeted maximum likeli-
hood estimation. The probability of ART initia-
tion, death, and HIV-associated tuberculosis or 
death were estimated in each community by the 
Kaplan–Meier method. Estimates of HIV care 
cascade coverage (i.e., the percentage of HIV-
infected persons who knew their status, the per-
centage of those who knew their status who had 
received ART, the percentage of those who had 
received ART who had HIV viral suppression, 
and the percentage of all HIV-infected persons 
with viral suppression) included data from per-
sons who migrated into the community (and 
were therefore not residents in the community at 
the time of baseline testing) and adjusted for 
missing data. Annual incidence rates of HIV in-
fection in communities in the intervention group 
were compared over time with the use of Poisson 
generalized estimating equations with an ex-
changeable covariance matrix.
R esult s
Trial Population
We enumerated 355,848 persons in the baseline 
census, of whom 150,395 were residents 15 years 
of age or older (Fig. 1). Of these residents, 45% 
were male and 96% were stable residents (defined 
as residents who had spent at least 6 months of 
the previous year in the trial community) (Ta-
ble 1). The demographic characteristics of the 
two trial groups were balanced at baseline (Ta-
ble S2 in the Supplementary Appendix). Male cir-
cumcision coverage varied across regions: 14% 
of the men in western Uganda, 40% in eastern 
Uganda, and 46% in Kenya reported having been 
circumcised (Fig. S5 in the Supplementary Ap-
pendix). Among 135,484 persons whose HIV 
serostatus was known, the baseline prevalence 
of HIV infection was 19% in Kenya, 7% in west-
ern Uganda, and 4% in eastern Uganda (Fig. S6 
in the Supplementary Appendix). Among 13,529 
persons known to be HIV-infected at baseline, 
52% had a CD4+ T-cell count of more than 500 
per cubic millimeter.
Population-Based HIV Testing and Uptake  
of Treatment
Before the start of baseline testing in the trial, 
approximately 57% of residents reported having 
undergone previous HIV testing (Fig. 2A). Dur-
ing baseline testing campaigns, we tested 90% 
of all census-enumerated residents in the inter-
vention group and 91% in the control group. 
After the first-year health campaigns in the 
intervention group, 92% of residents, including 
those who migrated into the communities, had 
undergone HIV testing at least once; this per-
centage increased to 94% after the second year. 
By the 3-year end-point assessment, we achieved 
cumulative HIV testing coverage of 98% of resi-
dents in the intervention group and 96% of resi-
dents in the control group, including residents 
who migrated into each of the two groups of 
communities.
Among 5952 HIV-infected persons with no 
previous or current ART use, the percentage of 
persons who initiated ART was higher in the 
intervention group than in the control group 
after 6, 12, 24, and 36 months (Fig. 2B). Similar 
trends were seen across all baseline strata of 
CD4+ T-cell counts (Fig. S7 in the Supplemen-
tary Appendix), including a CD4+ T-cell count of 
less than 350 per cubic millimeter, which was 
the threshold for eligibility for ART that had 
been indicated for all persons at the start of the 
trial. In the intervention group, population-level 
HIV RNA suppression among all HIV-infected 
persons increased from 42% at baseline to 71% 
after 1 year (Fig. 2C). At 3 years, an estimated 
92% of HIV-infected persons knew their status, 
95% of these persons had received ART, and 90% 
of those who received ART had viral suppression. 
In contrast, in the control group at 3 years, 91% 
of HIV-infected persons knew their status, 86% of 
them had received ART, and 87% of those who 
received ART had viral suppression (Table S3 in 
the Supplementary Appendix).
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At 3 years, among all HIV-infected persons, 
the prevalence of viral suppression was 15% 
higher in the intervention group than in the 
control group (79% vs. 68%; relative prevalence, 
1.15; 95% confidence interval [CI], 1.11 to 1.20) 
(Fig. 2C). In the intervention group at 3 years, 
the prevalence of viral suppression was higher 
among women (81%) than among men, but 74% 
of men still had viral suppression; viral suppres-
sion among youth 15 to 24 years of age was 55%. 
Trends across subgroups were similar in the 
control group, although the prevalence of viral 
suppression was consistently lower in the con-
trol group than in the intervention group among 
both men and women and across all age strata 
and all geographic regions. Among persons who 
began the trial with viral suppression, 96% of 
those in the intervention group and 95% of those 
in the control group maintained viral suppres-
sion after 3 years. (Detailed data are provided in 
Figs. S8 through S10 in the Supplementary Ap-
pendix.)
Incidence of HIV Infection
Among the 117,114 adults in the HIV-incidence 
cohort (which comprised persons who were at 
least 15 years of age, were stable residents, and 
were HIV-negative at baseline), the primary end 
point was evaluated in 49,590 of 61,676 persons 
(80%) in the intervention group and in 45,493 of 
55,438 persons (82%) in the control group (Figs. 
S11 and S12 in the Supplementary Appendix). A 
total of 704 confirmed new HIV infections were 
reported. The 3-year cumulative incidence of 
HIV infection in the intervention group was 
0.77% (0.25 cases per 100 person-years) and was 
Figure 1. Trial Cohort.
32 Communities underwent randomization
16 Were assigned to intervention
6 Were in Kenya
5 Were in western Uganda
5 Were in eastern Uganda
16 Were assigned to control
6 Were in Kenya
5 Were in western Uganda
5 Were in eastern Uganda
90,694 Were excluded
90,686 Were <15 yr of age
8 Had age unknown 
83,820 Were excluded
83,816 Were <15 yr of age
4 Had age unknown 
186,639 Persons were enumerated 169,209 Persons were enumerated
95,945 Were ≥15 yr of age 85,389 Were ≥15 yr of age
16,127 Were excluded
15,978 Were nonresidents
149 Died before baseline
14,812 Were excluded
14,707 Were nonresidents
105 Died before baseline
 7665 Died or left the community
1294 Died
6371 Migrated out of
community
79,818 Were residents who were ≥15 yr
 of age at baseline
70,577 Were residents who were ≥15 yr
 of age at baseline
8790 Died or left the community
1339 Died
7451 Migrated out of
community
28,158 Were added to cohort
14,013 Turned 15 yr of age
14,145 Migrated into
community
24,256 Were added to cohort
12,845 Turned 15 yr of age
11,411 Migrated into 
community
99,186 Were residents who were ≥15 yr
 of age at Yr 3
87,168 Were residents who were ≥15 yr
 of age at Yr 3
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not significantly different from the cumulative 
incidence in the control group (0.81%; 0.27 cases 
per 100 person-years) (relative risk, 0.95; 95% CI, 
0.77 to 1.17). Similarly, no significant differ-
ences in the 3-year cumulative incidence of HIV 
infection were observed either in prespecified 
subgroups (men, women, persons 15 to 24 years 
of age, persons older than 24 years, nonmobile 
persons, and uncircumcised men) or among geo-
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Figure 2. HIV Testing, Uptake of Treatment, and Viral 
Suppression.
Panel A shows the cumulative percentage of residents 
who underwent human immunodeficiency virus (HIV) 
testing before and during the trial. The values labeled 
as “before baseline” are the percentages of the 138,052 
residents (72,978 in the intervention group and 65,074 
in the control group) who reported at the time of base-
line testing that they had undergone previous HIV test-
ing. The remaining values in Panel A are the percentages 
of all residents at the time of annual testing (excluding 
persons who migrated out of the community and per-
sons who died and including persons who were newly 
15 years of age and persons who migrated into the com-
munity, identified through the second census that was 
conducted at year 3) who had at least one documented 
HIV test result. At baseline, the assessment included 
79,818 residents in the intervention group and 70,577 
residents in the control group; at year 1, the assessment 
included 89,994 residents in the intervention group, and 
at year 2, the assessment included 93,008 residents in the 
intervention group. Panel B shows the percentage of per-
sons who initiated antiretroviral therapy (ART) among HIV-
infected persons with no previous or current ART use at 
baseline. The assessment included 3002 residents in the 
intervention group and 2950 residents in the control group. 
Community-level estimates of the probability of initiating 
ART by 6, 12, 24, and 36 months were calculated by the 
Kaplan–Meier method; data from patients who died or 
who migrated out of the community were censored at 
the time of death or out-migration. The trial groups were 
compared with the use of community-level targeted maxi-
mum likelihood estimation. Panel C shows population-
level plasma HIV RNA suppression over time among HIV-
infected residents. The assessment included all residents 
at the time of annual testing (excluding persons who mi-
grated out of the community and persons who died, but 
including residents who were newly 15 years of age and 
those who migrated into the community, identified 
through the second census that was conducted at year 3). 
HIV RNA suppression was assessed in 5347 residents in 
the intervention group and in 4192 residents in the control 
group at baseline; in 6269 residents in the intervention 
group at year 1; in 6348 residents in the intervention group 
at year 2; and in 6800 residents in the intervention group 
and 6051 residents in the control group at year 3. Commu-
nity-level estimates of suppression were adjusted for in-
complete measures of HIV serostatus and HIV RNA with 
the use of individual-level targeted maximum likelihood 
estimation (adjustment variables included sex, age group, 
marital status, educational level, occupation, alcohol use, 
household wealth, mobility, previous HIV testing, and 
care status). The estimated total number of HIV-positive 
persons was 15,399 at baseline and was 15,748 at year 3. 
The trial groups were compared with the use of commu-
nity-level targeted maximum likelihood estimation. I bars 
in Panels B and C indicate 95% confidence intervals.
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graphic regions (Figs. S13 and S14 in the Supple-
mentary Appendix). The annual incidence of HIV 
infection, which was evaluated in the interven-
tion group only, declined over the course of the 
trial (Table 2). The annual incidence of HIV infec-
tion was estimated from cohorts of more than 
50,000 adults who were tested annually (Fig. S15 
in the Supplementary Appendix); the incidence 
at 3 years was 32% lower than that at 1 year 
(relative rate, 0.68; 95% CI, 0.56 to 0.84). De-
clines in the annual HIV incidence varied across 
regions, with a 46% reduction in Kenya, virtu-
ally no change in western Uganda, and a 39% 
reduction in eastern Uganda at 3 years. The de-
cline in the incidence among men was more 
than double that among women (50% vs. 18%) 
(Fig. S16 in the Supplementary Appendix).
Community Health Outcomes
The cumulative probability of death due to ill-
ness by year 3 among adults who were HIV-
positive at baseline (Fig. S17 in the Supplemen-
tary Appendix) was 23% lower in the intervention 
group than in the control group (3% vs. 4%; 0.99 
deaths per 100 person-years vs. 1.29 deaths per 
100 person-years; relative risk, 0.77; 95% CI, 
0.64 to 0.93). The overall rate of death due to 
illness among all adults (irrespective of HIV in-
fection) was 0.51 deaths per 100 person-years in 
the intervention group and 0.56 deaths per 100 
person-years in the control group (relative rate, 
0.90; 95% CI, 0.79 to 1.02). Among persons who 
were HIV-positive at baseline, the cumulative 
probability of incident tuberculosis or death due 
to illness by year 3 was 21% lower in the inter-
vention group than in the control group (4% vs. 
5%; 1.19 events per 100 person-years vs. 1.50 
events per 100 person-years; relative risk, 0.79; 
95% CI, 0.67 to 0.94); among persons with a 
CD4+ T-cell count of 500 or fewer per cubic milli-
meter, the cumulative probability was 29% lower 
in the intervention group than in the control 
group (5% vs. 7%; 1.62 events per 100 person-
years vs. 2.31 events per 100 person-years; rela-
tive risk, 0.71; 95% CI, 0.56 to 0.88). Effects were 
similar when persons with an unknown HIV 
status at baseline were included in the analysis 
(relative risk, 0.80; 95% CI, 0.69 to 0.91) (Fig. 
S18 in the Supplementary Appendix). In a post 
hoc comparison of the two trial groups, the in-
cidence rate of tuberculosis at 3 years among 
persons who were HIV-positive at baseline was 
59% lower in the intervention group than in the 
control group (relative rate, 0.41; 95% CI, 0.19 to 
0.86) (Fig. 3A), but the incidence rate of tubercu-
losis at 3 years did not differ significantly be-
tween the groups among persons who were 
HIV-negative at baseline (Fig. 3B).
At 3 years, among adults with prevalent hy-
pertension, the percentage who achieved control 
of their hypertension was 26% higher in the in-
tervention group than in the control group (47% 
vs. 37%; relative prevalence, 1.26; 95% CI, 1.15 
to 1.39). Among persons who were HIV-positive 
and had hypertension at baseline, the percentage 
of persons who had both HIV viral suppression 
and control of hypertension was 22% higher in 
the intervention group than in the control group 
(72% vs. 59%; relative prevalence, 1.22; 95% CI, 
1.08 to 1.37). Similar results were observed 
among persons who had diabetes or hyperten-
sion. (Details are provided in Figs. S19 through 
S21 in the Supplementary Appendix.)
Discussion
The 3-year cumulative incidence of HIV infection 
was not significantly lower in the intervention 
communities than in the control communities 
in rural Uganda and Kenya after a population-
level multidisease approach to HIV testing was 
Region Incidence Rate per 100 Person-Yr
Relative Rate 
(95% CI)†
Year 1 Year 2 Year 3
All regions 0.43 0.38 0.31 0.68 (0.56–0.84)
Kenya 0.69 0.62 0.39 0.54 (0.39–0.75)
Western Uganda 0.35 0.35 0.38 1.03 (0.73–1.44)
Eastern Uganda 0.29 0.19 0.18 0.61 (0.39–0.95)
*  The annual incidence rate of HIV infection per 100 person-years was calculated 
in three annual incidence cohorts of HIV-negative adults 15 years of age or old-
er (including nonstable residents, persons who migrated into the community, 
and persons who migrated out) who had repeat annual HIV testing. At year 1, 
the analysis included 52,474 persons, representing 51,975 person-years of fol-
low-up; at year 2, the analysis included 55,531 persons, representing 53,371 per-
son-years of follow-up; at year 3, the analysis included 58,145 persons, repre-
senting 52,567 person-years of follow-up. For incident infections, the date of in-
fection was imputed as the midpoint of the time between repeat HIV tests.
†  The relative rate (year 3 vs. year 1) was based on Poisson generalized estimat-
ing equations with an exchangeable covariance matrix, with adjustment for age, 
sex, and mobility (i.e., at least 1 month of the previous year spent outside the 
community).
Table 2. Change in the Annual Incidence of HIV Infection over Time  
in the Intervention Group.*
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implemented in all communities. However, the 
risk of death and the risk of tuberculosis or 
death among HIV-infected adults, as well as the 
prevalence of uncontrolled hypertension in all 
adults, were approximately 20% lower in the 
intervention communities than in the control 
communities.
In the assessment of a universal HIV test-and-
treat strategy that used a community-based, 
multidisease approach, HIV testing was per-
formed in 90% of adult residents in the interven-
tion group at baseline, a percentage that in-
creased to 94% by year 2; the time to initiation 
of ART was shorter in the intervention group 
than in the control group; and the percentage of 
HIV-infected persons with viral suppression in 
the intervention group exceeded both the per-
centage who had viral suppression in the control 
group and the UNAIDS target of 73%. The suc-
cess of our testing approach was also reflected 
in the control group, in which baseline HIV 
testing coverage was 91%, which provided an 
opportunity for persons to engage in HIV care 
and access ART as eligibility expanded.
We did not detect a significant difference 
between the groups in the cumulative incidence 
of HIV infection despite the fact that the per-
centage of HIV-infected persons with viral sup-
pression was 15% higher in the intervention 
group than in the control group after 3 years. 
The most likely explanation is that our active 
control with comprehensive baseline HIV testing 
and implementation of near-universal ART eligi-
bility 1 year after the start of our trial increased 
the prevalence of population-level viral suppres-
sion from 42% to 68%, which consequently re-
duced the difference between the groups in the 
number of persons who were capable of trans-
mitting HIV during the trial.4 Other possible 
explanations include infections from outside 
communities, outbreaks of acute HIV infection, 
and infection sources from a small subgroup of 
persons who had unsuppressed viral load — hy-
potheses that can be tested in future phyloge-
netic studies.13,14
Although no significant difference was ob-
served between the groups in the 3-year cumula-
tive incidence of HIV infection, the annual inci-
dence of HIV infection in the intervention group 
declined by 32% between the first and third 
years. These data support accumulating evidence 
from other large universal test-and-treat and 
cohort studies in sub-Saharan Africa that popu-
lation-level increases in viral suppression are 
associated with a reduction in the incidence of 
HIV infection.15-19 Because our trial included an 
active control group, we were unable to directly 
quantify the contribution of the SEARCH treat-
ment intervention to the decline in HIV inci-
dence. However, a mathematical model of 
SEARCH communities suggested that the inter-
vention resulted in a lower incidence than that in 
a nonactive control; modeled HIV incidence in 
the third year was 0.4% with the SEARCH inter-
vention, an incidence that was close to the ob-
Figure 3. Incidence of Tuberculosis over Time.
Panel A shows the incidence rates of tuberculosis over time among residents 
who were HIV-positive at baseline and who had not received a diagnosis of 
active tuberculosis at baseline (13,430 residents). Panel B shows the incidence 
rates of tuberculosis over time among residents who were HIV-negative at 
baseline and who had not received a diagnosis of active tuberculosis at base-
line (121,604 residents). For both analyses, data for person-time at risk were 
censored at the time of migration out of the community, death, or diagnosis 
of active tuberculosis, and the trial groups were compared at 3 years with the 
use of community-level targeted maximum likelihood estimation.
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served incidence of 0.3% and that was 43% 
lower than the incidence of 0.7% that was pre-
dicted by the model without any SEARCH activi-
ties.20 We observed marked regional variations 
in the incidence of HIV infection from the first 
year to the third year, including a 46% decline in 
Kenya, where the prevalence of HIV infection 
was highest, and virtually no change in western 
Uganda, where the contribution of lower male 
circumcision coverage and migration of HIV-in-
fected persons into the area is under investiga-
tion. In addition, declines in the incidence of 
HIV infection were less pronounced among 
women than among men, despite a high preva-
lence of viral suppression among men in a re-
gion in which HIV transmission to women oc-
curs primarily through heterosexual encounters; 
both biologic and behavioral factors may have 
played a role.
We hypothesized that the SEARCH interven-
tion would improve community health out-
comes. Indeed, by year 3, we observed a cumula-
tive probability of death among HIV-infected 
persons that was 23% lower in the intervention 
group than in the control group, an annual inci-
dence rate of tuberculosis among HIV-infected 
persons that was 59% lower in the intervention 
group than in the control group, and a preva-
lence of control of hypertension in the overall 
population that was 26% higher in the interven-
tion group than in the control group. We attri-
bute these gains to our multidisease care model 
and patient-centered delivery of universal ART, 
which accelerated ART initiation among persons 
who had not been receiving treatment across all 
strata of CD4+ T-cell counts, including the stra-
tum of less than 350 cells per cubic millimeter, 
the level at which the risk of death and tubercu-
losis are highest and at which all persons in both 
trial groups were eligible for immediate treat-
ment.21 Our trial provides evidence that the way 
in which care is delivered can affect clinical out-
comes, including death, tuberculosis, and hyper-
tension, during efforts that are directed at HIV 
elimination.22-24
This trial had several limitations. First, because 
the control group had near-universal baseline 
HIV testing, we were unable to directly compare 
our intervention with the standard-of-care ap-
proaches used in the two countries. However, 
our data suggest that additional annual testing 
did not further reduce the incidence of HIV infec-
tion. Second, rapid implementation of expand-
ing ART eligibility may have limited our ability 
to detect a significant difference between the 
trial groups, although universal treatment is now 
the global standard and, hence, the relevant com-
parison. Finally, results for the end point of tu-
berculosis relied on registry data, and results for 
the end point of death relied on information 
from family members or community members; 
however, ascertainment of these end points did 
not differ substantially between the groups.
An estimated 680 million persons will reside in 
rural sub-Saharan Africa by 2020. The SEARCH 
community health model is one approach to the 
reduction of HIV-associated deaths, tuberculosis, 
and other chronic diseases in rural sub-Saharan 
Africa, an approach that is in step with the 
United Nations Sustainable Development Goals. 
Our cost for a one-time health campaign was 
within the range of other mobile HIV testing 
approaches, and hypertension and diabetes test-
ing added only $1 (U.S.) per person.25 Similarly, 
our cost for patient-centered care was similar to 
that reported by large funding agencies.26 The 
fact that the percentage of HIV-infected persons 
with viral suppression in our trial exceeded the 
UNAIDS target of 73% is an important step for-
ward, but reducing the incidence of HIV infec-
tion to below 0.1% will require additional ap-
proaches to treatment and prevention that may 
be enhanced by a broader multidisease model 
incorporating cost and care delivery.27,28
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